Impact Events
Callista Industries: Ravi Jabbar Sharma Acquires 4,00,000 Equity Shares
Ravi Jabbar Sharma has acquired 4,00,000 equity shares in Callista Industries Ltd through the conversion of convertible warrants. This acquisition represents 1.39% of the total diluted share capital. Following the transaction, Sharma's total holding in the company, including warrants, stands at 16,00,000 shares, representing 5.56% of the total diluted capital. The equity share capital of the company increased from Rs. 10,00,00,000/- to Rs. 10,40,00,000/-.
SBI Mutual Fund Sells 1.47 Lakh Shares of Pakka Ltd
SBI Mutual Fund has sold 1,47,883 shares of Pakka Ltd, representing 0.2869% of the paid-up share capital. This sale reduces their total holding to 20,59,687 shares, which is 3.9957% of the company's paid-up share capital. The previous holding was 4.6311%. The transaction occurred on October 19, 2026, via market sale. The total equity share capital of Pakka Ltd is Rs. 51,54,81,000/-.
Renew Exim DMCC Reduces Cemindia Projects Holding by 1.50%
Renew Exim DMCC has reduced its shareholding in Cemindia Projects Limited. The transaction involved a reduction of 1,26,35,379 equity shares, representing a 1.50% decrease in voting rights. Following the transaction, Renew Exim DMCC's holding stands at 11,58,92,883 shares, which is 62.84% of the total diluted share capital. The reduction in voting rights is a result of the Target Company issuing further equity shares to Qualified Institutional Buyers, leading to a dilution of the promoter's voting rights.
Rose Merc Ltd: Harshee Anil Haria Acquires Shares via ESOP
Rose Merc Limited has disclosed an acquisition of 1,72,000 equity shares of Rs. 10/- each by Harshee Anil Haria. The acquisition was made through allotment under the Employee Stock Option Plan (ESOP). This disclosure is made as per Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition occurred between August 6, 2026, and October 19, 2026.
DCM Shriram Clarifies No Price Sensitive Information
DCM Shriram Industries Ltd has responded to queries from BSE and NSE regarding recent price movements. The company stated that there have been no new developments in its operations that would constitute price-sensitive information requiring disclosure under SEBI regulations. The company affirmed its commitment to promptly disclosing any material information as per listing regulations and to updating its website accordingly.
SBI Mutual Fund Buys 50,621 Shares of Elevate Campuses
SBI Mutual Fund, through its various schemes, has purchased 50,621 shares of Elevate Campuses Ltd, representing a 0.03% stake. This transaction increases SBI Mutual Fund's total holding to 9.1997% (1,55,04,361 shares) from a previous holding of 7.1799%. The acquisition occurred on October 16, 2026, with a transaction value of ₹16,85,31,037. This disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
SBI Mutual Fund Acquires 5.25% Stake in ASM Technologies
SBI Mutual Fund, through its various schemes, has acquired 8,22,564 shares of ASM Technologies Ltd on October 16, 2026, representing 5.2501% of the company's paid-up share capital. This acquisition was made through a preferential allotment. The total holding of SBI Mutual Fund after the acquisition stands at 8,22,564 shares. The transaction was disclosed under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Biogen Pharmachem: Rama Shiva Lease Finance Sells 4.04% Stake
Biogen Pharmachem Industries Ltd has announced a significant shareholding change. Rama Shiva Lease Finance Private Limited has sold its entire stake of 4,25,83,333 shares, representing 4.04% of the total share capital. The transaction was conducted via the open market. Following the sale, Rama Shiva Lease Finance Private Limited holds 0% of the company's equity. The total equity share capital of Biogen Pharmachem Industries Ltd remains Rs. 1,05,30,36,833, divided into 105,30,36,833 equity shares of Rs. 1/- each.
Omprakash Partani Acquires 6.47% Stake in Capricorn Systems
Omprakash Partani, along with his son Krishna Kumar Partani (acting in concert), has acquired a 6.471% stake in Capricorn Systems Global Solutions Ltd. The acquisition involved 9,93,541 equity shares purchased through open market transactions on BSE. Prior to this acquisition, their combined holding was 3.243%. Both the acquirer and the Persons Acting in Concert (PACs) are classified under the public/non-promoter category. The total equity share capital of the company remains ₹27,97,20,000, comprising 2,79,72,000 equity shares of face value ₹10 each.
Deepak Builders Promoter Pledges 20 Lakh Shares for Personal Use
Mr. Deepak Kumar Singal, Promoter of Deepak Builders and Engineers India Ltd, has disclosed the creation of a pledge on 20,00,000 equity shares, representing 0.43% of the total share capital and 0.66% of his promoter shareholding. The encumbrance, created on October 17, 2026, is a pledge in favour of Comfort Fincap Limited for personal use by the promoter. The value of the encumbered shares on the date of the event was ₹1,27,00,000, with an amount involved of ₹4,00,00,000.
Deepak Builders Promoter Pledges 20 Lakh Shares for Personal Use
Mr. Deepak Kumar Singal, promoter of Deepak Builders and Engineers India Ltd, has created a pledge over 20,00,000 equity shares, representing 0.43% of the total share capital and 0.66% of his promoter shareholding. The encumbrance, a pledge, was created on October 17, 2026, with Comfort Fincap Limited as the beneficiary. The stated reason for the pledge is personal use by the promoter. This action increases the total promoter-held encumbered shares to 56,400,000, or 12.11% of the total share capital.
Ritu Jain Acquires 5.5 Lakh Warrants in Mangal Credit
Ritu Jain, a promoter of Mangal Credit and Fincorp Limited, has acquired 5,50,000 Convertible Equity Warrants through a preferential allotment. This acquisition represents 2.33% of the total diluted share capital of the company. The total equity share capital of the company before and after the acquisition remains 21,11,39,860 shares, but the diluted share capital increases to 23,61,39,860 shares post-warrant issuance.
Seema Ajit Jain Acquires 5.5 Lakh Warrants in Mangal Credit
Seema Ajit Jain has acquired 5,50,000 Convertible Equity Warrants in Mangal Credit and Fincorp Limited through a preferential allotment. This transaction increases her total holding of warrants to 5,50,000. Her shareholding in terms of shares remains unchanged at 1,25,276 shares, representing 0.59% of the total capital. The total diluted share capital of the company after this acquisition is 23,61,39,860.
Shri Dinesh Mills: Promoter group to gift 24.22% shares
Shri Dinesh Mills Limited has received a disclosure regarding the proposed inter-se transfer of shares among its promoter and promoter group. Nimish Upendrabhai Patel, jointly with Arushaben Nimishbhai Patel, will acquire 7,68,852 shares (13.73%). Nishank Nimishbhai Patel, jointly with Arushaben Nimishbhai Patel, will acquire 5,04,490 shares (9.01%). Arushaben Nimishbhai Patel, jointly with Nimish Upendrabhai Patel, will acquire 83,085 shares (1.48%). The total acquisition amounts to 13,56,427 shares, representing 24.22% of the total share capital. This transfer is proposed to be executed by way of gift, falling under the exemption provided in Regulation 10(1)(a)(i) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Consequently, there will be no change in the overall shareholding of the Promoter and Promoter Group. The rationale behind this transaction is a private family arrangement to streamline the family's assets and businesses.
Lupin Appoints Brian Savage as President, Chief Legal Officer
Lupin Limited has announced the appointment of Brian Savage as its new President and Chief Legal Officer. Based in New Jersey, Savage will oversee Lupin's global Legal, Compliance, and Intellectual Property Management Group (IPMG) functions. He brings extensive experience from Teva Pharmaceuticals, where he held senior legal leadership roles, including Executive Vice President and Interim Global Chief Legal Officer. His appointment is expected to strengthen Lupin's governance framework and support its growth ambitions in the evolving regulatory landscape of the global pharmaceutical industry.